Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
73°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
AbbVie
(NY:
ABBV
)
189.26
-2.14 (-1.12%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 18, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about AbbVie
< Previous
1
2
3
4
5
6
7
8
9
...
74
75
Next >
My Top 2 Earnings Picks For This Earnings Season
July 16, 2025
Via
Benzinga
Looking Into AbbVie's Recent Short Interest
July 16, 2025
Via
Benzinga
1 Unpopular Stock that Deserves Some Love and 2 to Steer Clear Of
July 14, 2025
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other...
Via
StockStory
3 Dividend Growth Stocks to Buy and Hold
July 12, 2025
Via
The Motley Fool
Topics
Intellectual Property
The Smartest Dividend Stocks to Buy With $300 Right Now
July 12, 2025
Via
The Motley Fool
Topics
Energy
Government
World Trade
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
July 11, 2025
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.
Via
Benzinga
Topics
Government
World Trade
Boeing, Joby Aviation, Oracle And A Health Care Stock: CNBC's 'Final Trades'
July 11, 2025
The investment landscape is shifting as companies show resilience and innovation, prompting investors to reassess portfolios. AbbVie, Boeing, Oracle, and Joby Aviation mentioned as potential...
Via
Benzinga
What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill
July 11, 2025
A steady dose of quality companies will keep your portfolio growing big and strong.
Via
The Motley Fool
Topics
Intellectual Property
AbbVie Enters Licensing Agreement For IGI Therapeutics’ Experimental Oncology Drug: Retail Cheers
July 10, 2025
Under the terms of the agreement, AbbVie will receive exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China.
Via
Stocktwits
Topics
Product Recall
Why Is AbbVie Stock Trading Higher On Thursday?
July 10, 2025
AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase clinical data.
Via
Benzinga
Trump Threatens 200% Tariffs On Drug Imports, Says Big Pharma Will Get Some Time 'To Get Their Act Together'
July 08, 2025
Pharmaceutical investors are being cautious, with concerns over potential supply disruptions, cost pressures, and uncertainty regarding policy implementation.
Via
Stocktwits
Topics
ETFs
Economy
Government
3 No-Brainer Stocks to Buy in July
July 07, 2025
Via
The Motley Fool
2 Dividend Stocks to Buy for Decades of Passive Income
July 06, 2025
Via
The Motley Fool
Topics
Intellectual Property
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
July 05, 2025
Via
The Motley Fool
Topics
Economy
Intellectual Property
AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment
July 03, 2025
Via
Benzinga
Novartis' Cosentyx Fails Late-Stage Giant Cell Arteritis Trial
July 03, 2025
Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial data.
Via
Benzinga
3 Profitable Stocks Skating on Thin Ice
July 03, 2025
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...
Via
StockStory
HDV Is a Popular Dividend ETF for Passive Income. But Is It the Best?
July 01, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
ETFs
Stocks
AbbVie To Acquire Capstan Therapeutics For Up To $2.1 Billion To Boost Immunology Portfolio As Humira Sales Drop: Stock Gains In Morning Trade
June 30, 2025
The acquisition will include Capstan’s lead asset, called CPTX2309, in development for the treatment of B-cell-mediated autoimmune diseases.
Via
Stocktwits
Topics
Intellectual Property
3 Dividend Stocks to Double Up on Right Now
June 29, 2025
Via
The Motley Fool
Topics
Government
World Trade
Got $500? 2 Healthcare Stocks to Buy and Hold Forever
June 28, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes
June 26, 2025
Bill Meury will take the place of Herve Hoppenot, who is retiring after 11 years at Incyte's helm.
Via
Investor's Business Daily
Obesity Drugs Help With Weight Loss But Are Adding Fat Elsewhere
June 20, 2025
The U.S. trade deficit with Ireland has surged as $36 billion in hormone shipments for weight-loss and diabetes drugs were flown in to meet demand and avoid tariffs.
Via
Benzinga
Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'
June 20, 2025
A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices.
Via
Benzinga
AbbVie's Migraine Drug Outperforms Generic Treatment In Head-To-Head Trial
June 18, 2025
AbbVie's atogepant showed fewer side effects and greater efficacy than topiramate in a Phase 3 migraine prevention trial.
Via
Benzinga
AbbVie’s Migraine Drug Yields Positive Outcome In Late-Stage Study Versus Topiramate, But Fails To Draw Retail Cheer
June 18, 2025
Atogepant had fewer discontinuations in the study involving 545 participants due to adverse events than Topiramate.
Via
Stocktwits
Topics
Economy
AI Meets Oncology: Caris Life Sciences' $5.35B IPO Tests Investor Appetite for Precision Medicine
June 17, 2025
Via
Benzinga
Topics
Artificial Intelligence
Initial Public Offering
Elizabeth Warren, Jan Schakowsky Reportedly Seek Answers From Pfizer, Amgen, And Others On Low Federal Tax Bills
June 17, 2025
The Democratic lawmakers alleged that pharmaceutical companies avoided paying U.S. tax bills by shifting their profits to offshore subsidiaries in jurisdictions with significantly lower tax rates, such...
Via
Stocktwits
Topics
Government
AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For Myelodysplastic Syndromes
June 17, 2025
AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of venetoclax remain unchanged.
Via
Benzinga
Roche Stock Slides After Failed Blood Cancer Trial With AbbVie, But Parkinson’s Therapy Progress Boosts Retail Mood
June 16, 2025
The Swiss pharma giant advanced its anti-alpha-synuclein antibody prasinezumab to the next stage based on promising Phase IIb data.
Via
Stocktwits
< Previous
1
2
3
4
5
6
7
8
9
...
74
75
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.